Agendia B.V. (Amsterdam, The Netherlands) and Erasmus MC, University Medical Center Rotterdam ( Rotterdam, The Netherlands) have signed a license agreement that provides Agendia with the exclusive rights to a genetic profile developed by Erasmus MC that predicts resistance to tamoxifen -- one of the most widely used hormonal therapies in breast cancer. Agendia will validate the tamoxifen profile in collaboration with the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI/AVL, Amsterdam, The Netherlands). Once validated the profile can be offered along with Agendia’s product MammaPrint to further expand its offering in breast cancer.
